Table 4_Is full adherence mandatory? Real-world outcomes of completing perioperative chemo

A clinical study by Zhoujunyi Tian, last updated in May 2026, compares outcomes for patients with resectable non-small cell lung cancer who did or did not complete a full perioperative chemoimmunotherapy regimen. The dataset includes 164 patients divided into a completed group (n=37) and a non-completed group (n=127), with analyses of recurrence-free survival, overall survival, and adverse events.

Use Cases

• Compare recurrence-free survival based on treatment completion status.
• Analyze overall survival outcomes between patient groups using Kaplan-Meier methods.
• Assess predictors of cancer recurrence based on pathological nodal status.
• Evaluate the incidence of adverse events associated with completing the full therapy regimen.
• Perform subgroup analysis on outcomes for patients aged <65 years with ECOG score 0.

Strengths

• Includes 164 patient records from a real-world clinical setting.
• Uses Inverse Probability of Treatment Weighting to adjust for baseline characteristics.
• Reports specific statistical results, including hazard ratios and p-values for survival comparisons.

Limitations

• Row count for individual variables is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 17.3 KB, indicating limited scope.

Provenance

Source

Zhoujunyi Tian via figshare

Collection Method

Retrospective clinical study of patients who received neoadjuvant chemoimmunotherapy followed by surgery.

Freshness

Last updated 2026-05-28 04:45:41; freshness should be verified.